UNSPSC 51282319: Erythromycin f

This classification denotes a macrolide antibiotic with the molecular formula C37H67NO14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NM325T380N, chemically known as erythromycin, 16-hydroxy-, but more generally known as erythromycin f, which bears US NIH Compound Identifier 6426644. European Medicines Agency schedules erythromycin f or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06605MIG. Most nations, for tariff purposes, schedule erythromycin f under HS 29415000.

SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)CO)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O.

UNSPSC 51282319 Erythromycin f (Commodity) does not align with the state and local procurement activity currently tagged to this code. The most recent opportunities posted under this UNSPSC code involve naloxone procurement, first-aid and emergency medical supplies, generic pharmaceutical distribution through cooperative purchasing, and direct-to-manufacturer pharmacy programs — none of which concern erythromycin or a single-drug category at the commodity level. The mismatch suggests either a cataloging error in the source records or a significant divergence between the code's nominal scope and actual state and local buying patterns. State and local governments show no recent documented activity for erythromycin f as a discrete procurement item.

Geographic activity under the tagged opportunities spans Florida (Seminole County), Texas (Texas Health and Human Services Commission), and Minnesota-based cooperative purchasing serving multiple states including Oregon, with the City of Tampa also soliciting related medical supplies. However, because the posted opportunities do not substantively address the erythromycin commodity itself, these jurisdictions do not represent actual demand for this specific pharmaceutical. Any vendor pursuing opportunities under this code should verify current UNSPSC alignment with issuing bodies before bid development, as the code appears to misclassify the pharmaceutical products state and local agencies are currently buying.